利塞膦酸的人群药代动力学模型:吸收与低血浆水平描述
本研究基于四周期、双序列、单剂量交叉生物等效性试验的血浆浓度-时间数据,建立利塞膦酸的人群药代动力学模型,描述其吸收和低血浆水平特征。模型采用二室模型加滞后时间、一级吸收和消除,发现外周分布(骨骼)程度极高,志愿者特征未显著影响处置。模拟显示不同给药方案下浓度水平差异大,肾功能不全虚拟患者血药水平升高但无需调整剂量。
要点
- 利塞膦酸口服后动力学符合二室模型加滞后时间、一级吸收和消除。
- 外周分布(骨骼)程度极高,志愿者特征未显著影响药物处置。
- 模拟显示不同给药方案浓度差异大,肾损患者无需剂量调整。
核心结论
- 利塞膦酸的吸收和处置动力学被成功表征。
- 模拟显示不同给药方案下浓度水平差异大,提示其安全性特征。
- 肾功能不全虚拟患者血药水平升高,但无需剂量调整。
研究设计与样本
- 基于四周期、双序列、单剂量交叉生物等效性试验的血浆浓度-时间数据。
- 采用非线性混合效应模型,在MonolixTM 2020R1中实现建模与模拟。
- 测试体重、白蛋白、肌酐、碱性磷酸酶和钙等协变量对模型参数的影响。
主要发现
- 口服利塞膦酸后动力学最佳描述为二室模型加滞后时间、一级吸收和消除。
- 外周分布(骨骼)程度极高。
- 未发现志愿者特征显著影响利塞膦酸的处置。
- 模拟获得不同剂量和给药频率下的利塞膦酸血浆谱。
临床怎么用
- 肾功能不全患者使用利塞膦酸无需调整剂量。
- 不同给药方案下血药浓度差异大,临床需关注其安全性特征。
局限性
- 数据来源于单剂量生物等效性试验,可能未覆盖长期给药情况。
- 模拟基于虚拟患者,需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: To develop a population pharmacokinetic model that describes the absorption and low plasma levels of risedronate in the body. The impact of patients' characteristics on risedronate kinetics is investigated. Simulations revealed the high variability in the concentration levels after different dosage schemes. No dosage adjustment is required in renal impairment. INTRODUCTION: Risedronate exhibits very low plasma levels and high residence time in the body. The aim of this study is to describe and explain the risedronate transit through the body. The impact of volunteers' characteristics on the kinetics of risedronate is also investigated. Simulations are used to compare the risedronate plasma levels after different dosage schemes and assess the need for dose adjustment in patients with impaired kidney functionality. METHODS: Plasma concentration-time data were obtained from a four-period, two sequence, single-dose, crossover bioequivalence study. The effects of several covariates (e.g., weight, albumin, creatinine, alkaline phosphatase, and calcium) on model parameters were tested. Non-linear mixed-effect modeling was applied and a variety of models were evaluated placing emphasis on absorption and disposition properties. The modeling and simulation work was implemented in MonolixTM 2020R1. RESULTS: Following oral administration, the kinetics of risedronate was best described by a two-compartment model with lag time, first-order absorption, and elimination. The extent of peripheral distribution (i.e., bones) was found to be remarkably high. No volunteer characteristics were identified to affect significantly the disposition of risedronate. Using simulations, risedronate plasma profiles were obtained for different doses and frequencies of administration. CONCLUSION: The absorption and disposition kinetics of risedronate were successfully characterized. Simulations revealed the high discrepancy in the concentration levels observed after different dosage regimens, implying the safety profile of risedronate. In virtual patients with renal impairment, the blood levels of risedronate are increased, but not in an extent requiring dose adaptation.
引用
- Cardozo B, Karatza E, Karalis V, et al. Osteoporosis treatment with risedronate: a population pharmacokinetic model for the description of its absorption and low plasma levels. Osteoporos Int. 2021. PMID: 34002251. doi:10.1007/s00198-021-05944-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。